行情

CATB

CATB

Catabasis制药
NASDAQ

实时行情|Nasdaq Last Sale

2.740
+0.150
+5.79%
盘后: 2.680 -0.06 -2.19% 17:26 01/21 EST
开盘
2.640
昨收
2.590
最高
2.830
最低
2.570
成交量
115.89万
成交额
--
52周最高
8.59
52周最低
1.250
市值
5,503.11万
市盈率(TTM)
-1.2796
分时
5日
1月
3月
1年
5年
新闻
财报
公告
公司事件
分析
简况
Catabasis Pharmaceuticals Q3 EPS $(0.56), Same YoY
Catabasis Pharmaceuticals (NASDAQ:CATB) reported quarterly losses of $(0.56) per share. This is unchanged from the same period last year.
Benzinga · 2020/11/12 21:13
The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 29)
Benzinga · 2020/10/30 12:09
The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 28)
Benzinga · 2020/10/29 11:30
每日生物技术动向:赛诺菲-葛兰素史克向COVID-19疫苗联盟提供2亿剂剂量,吉利德收益,Biodesix首次亮相
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 27) * Amicus Therapeutics, Inc. (NASDAQ: FOLD) * Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) * Ascendis Pharma A...
Benzinga · 2020/10/28 12:41
Mid-Afternoon Market Update: Crude Oil Rises 3%; Scholar Rock Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded down 0.24% to 27619.44 while the NASDAQ rose 0.74% to 11,443.67. The S&P also rose, gaining 0.12% to 3,405.03.
Benzinga · 2020/10/27 18:31
Mid-Day Market Update: Harley-Davidson Jumps Following Strong Q3 Results; Catabasis Pharmaceuticals Shares Plummet
Midway through trading Tuesday, the Dow traded down 0.39% to 27578.44 while the NASDAQ rose 0.64% to 11,431.90. The S&P also fell, dropping 0.05% to 3,399.20.
Benzinga · 2020/10/27 16:19
Mid-Morning Market Update: Markets Mostly Lower; 3M Tops Q3 Estimates
Following the market opening Tuesday, the Dow traded down 0.34% to 27590.67 while the NASDAQ rose 0.14% to 11374.46. The S&P also fell, dropping 0.18% to 3,394.96.
Benzinga · 2020/10/27 14:21
The Daily Biotech Pulse: Catabasis Halts Duchenne Muscular Dystrophy Study, Lilly's COVID-19 Trial Disappointment, Merck, Pfizer Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 26) * Amicus Therapeutics, Inc. (NASDAQ: FOLD) * Beam Therapeutics Inc (NASDAQ: BEAM) * Blueprint Medicines Corp (NASDAQ: BPMC) * EXACT Sciences Corporation (NASDAQ: EXAS) * Kodiak Sciences Inc (NASDAQ: KOD) * Mirati Therapeutics Inc (NASDAQ: MRTX) (reacted to a positive clinical data readout) * Repligen Corporation (NASDAQ: RGEN) * Spruce Biosciences Inc (NASDAQ: SPRB)Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 26) * Avenue Therapeutics Inc (NASDAQ: ATXI) * Baudax Bio Inc (NASDAQ: BXRX) * Biogen Inc (NASDAQ: BIIB) * DBV Technologies ADR Representing 0.5 Ord Shs (NASDAQ: DBVT) * Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) * Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) * Gilead Sciences, Inc. (NASDAQ: GILD) * Jaguar Health Inc (NASDAQ: JAGX) * Kiromic Biopharma Inc (NASDAQ: KRBP) * Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) * Oncternal Therapeutics Inc (NASDAQ: ONCT) * Opiant Pharmaceuticals Inc (NASDAQ: OPNT) * Psychemedics Corp. (NASDAQ: PMD) * Recro Pharma Inc (NASDAQ: REPH) * Rockwell Medical Inc (NASDAQ: RMTI) * Teligent Inc (NEW JERSEY) (NASDAQ: TLGT) * Tricida Inc (NASDAQ: TCDA)Stocks In Focus Catabasis Ends Duchenne Muscular Dystrophy Trials After Failed Late-Stage Study Catabasis Pharmaceuticals Inc (NASDAQ: CATB) said the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy did not meet the primary endpoint, which was a change from baseline in the North Star Ambulatory Assessment over one year.The secondary endpoint of timed function tests such as time to stand; 10-meter walk/run; and four-stair climb also did not show statistically significant improvements, the company said.Consequently, the company said it is stopping activities related to the development of edasalonexent, including the ongoing GalaxyDMD open-label extension trial. Catabasis also said it plans to work with external advisors to explore and evaluate strategic options going forward.The stock was down 64.18% at $1.92 premarket Tuesday.Dexcom Pre-Announces Q3 Revenue, Announces Retirement Of Chief Commercial Officer DexCom, Inc. (NASDAQ: DXCM) preannounced third-quarter revenues of $500.9 million, representing 26% year-over-year growth. Analysts, on average, estimate revenues of $476.75 million.The company also announced that longtime executive Rick Doubleday, who is serving as chief commercial officer, will retire at the end of 2020.The stock was down 5.26% at $396 premarket. Lilly's Antibody Monotherapy Candidate Found Ineffective In Advanced COVID-19 Eli Lilly And Co's (NYSE: LLY) updated data from the NIAID-sponsored ACTIV-3 clinical trial evaluating the efficacy of its bamlanivimab in hospitalized COVID-19 patients suggests the antibody treatment candidate is unlikely to help them recover from this advanced stage of their disease, the company said in a statement. No additional COVID-19 patients in this hospitalized setting will receive bamlanivimab, Lilly said. All other studies are ongoing, including the NIH-sponsored ACTIV-2 trial testing bamlanivimab in recently diagnosed mild to moderate COVID-19 patients; the BLAZE-1 Phase 2 trial that is evaluating bamlanivimab monotherapy and in combination with etesevimab in recently-diagnosed COVID-19 patients in a non-hospitalized setting; and the BLAZE-2 Phase 3 trial that is evaluating bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities. View more earnings on IBBLilly shares were down 4.57% premarket at $135.23. Related Link: The Week Ahead In Biotech: Kala FDA Decision, Merck & Pfizer Earnings, Vaccine Updates And IPOs Novartis Q3 Beats Estimate, Company Raises FY20 Core Operating Income Guidance Novartis AG's (NYSE: NVS) third-quarter net sales from continuing operations rose 1% to $12.26 billion, and its core operating income climbed 9% due to lower spending and improved gross margin. Core EPS came in at $1.52, ahead of the $1.45 consensus estimate.The company raised its 2020 core operating income guidance from low double-digit growth to low double-digits-to-mid-teens percentage growth. The company expects net sales to grow by mid-single digits.Exelixis Says Japanese Partner Files For Label Expansion For Combo Drug To Treat Renal Cancer Exelixis, Inc. (NASDAQ: EXEL) said its Japanese partner Takeda Pharmaceutical Co Ltd (NYSE: TAK) and Ono Pharma have submitted a supplemental application to the Japanese Ministry of Health, Labour and Welfare for manufacturing and marketing approval of Cabometyx in combination with Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo for the treatment of patients with unresectable, advanced or metastatic renal cell carcinoma.NantKwest Appoints Veteran Health Care Exec Richard Adcock As CEO Nantkwest Inc (NASDAQ: NK) announced the appointment of Richard Adcock as its CEO effective immediately. Adcock will replace Patrick Soon-Shiong, who will become executive chairman of the board.The stock was up 0.89% at $9.11 premarket Tuesday.Aerpio Begins Midstage Study Of Razuprotafib In Moderate-To-Severe COVID-19 Patients Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) said it has begun dosing of the first patient with razuprotafib in the military-sponsored Phase 2 trial targeting the prevention and treatment of acute respiratory distress syndrome in patients with moderate-to severe COVID-19.The stock was down 0.78% premarket at $1.27. FDA OKs Vanda To Initiate Midstage Allergic Conjunctivitis Study Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) said the FDA has approved an investigational new drug application to evaluate the cystic fibrosis transmembrane conductance regulator activator VSJ-110 for the treatment of allergic conjunctivitis.Vanda said it plans to initiate enrollment in the Phase 2 study by the end of 2020 and anticipates results of this study in 2021.The stock rose 2.59% to $10.70 in after-hours trading.Offerings Mirati, which announced positive early-stage results for its KRAS G12C inhibitor MRTX849 in non-small cell lung cancer, said it intends to offer $700 million in shares of common stock in an underwritten public offering, and a selling stockholder intends to offer 375,000 shares in the offering.The stock slid 2.89% to $191 in after-hours trading.On The Radar Clinical Readouts Galera Therapeutics Inc (NASDAQ: GRTX) is due to present at the ASTRO annual meeting data from its Phase 1b/2a clinical trial of avasopasem manganese (GC4419) in combination with stereotactic body radiation therapy for locally advanced pancreatic cancer. The presentation is scheduled between 3 p.m. and 4:15 p.m.Earnings * Laboratory Corp. of America Holdings (NYSE: LH) (before the market open) * Merck & Co., Inc. (NYSE: MRK) (before the market open) * Pfizer Inc. (NYSE: PFE) (before the market open) * NeoGenomics, Inc. (NASDAQ: NEO) (before the market open) * Masimo Corporation (NASDAQ: MASI) (after the close) * DexCom (after the close) * Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) (after the close) * Omnicell, Inc. (NASDAQ: OMCL) (after the close) * Zynex Inc. (NASDAQ: ZYXI) (after the close)Related Link: Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates See more from Benzinga * Click here for options trades from Benzinga * The Week Ahead In Biotech: Kala FDA Decision, Merck & Pfizer Earnings, Vaccine Updates And IPOs * The Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebia's Positive Readout, Foghorn IPO(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 2020/10/27 13:24
更多
财务预测
每股收益每股净资产每股现金流
实际值(美元)
预测值(美元)
利润表更多
净利润营业总收入营业利润
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流投资现金流筹资现金流
经营现金流(美元)
同比(%)
了解CATB最新的财务预测,通过CATB每股收益,每股净资产,每股现金流等数据分析Catabasis制药近期的经营情况,然后做出明智的投资选择。
分析师评级

2位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测CATB价格均价为24.00,最高价位24.00,最低价为24.00。
EPS
机构持股
总机构数: 69
机构持股: 1,087.52万
持股比例: 54.15%
总股本: 2,008.43万
类型机构数股数
增持
16
38.42万
建仓
13
2.42万
减持
16
16.68万
平仓
0
0
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-1.04%
制药与医学研究
-0.53%
高管信息
Chairman/Independent Director
Kenneth Bate
President/Chief Executive Officer/Co-Founder/Director
Jill Milne
Chief Financial Officer
Noah Clauser
Senior Vice President/General Counsel
Benjamin Harshbarger
Chief Scientific Officer
Andrew Nichols
Other
Edward Hibben
Other
Joanne Donovan
Other
Andrew Komjathy
Independent Director
Burt Adelman
Independent Director
Joanne Beck
Independent Director
Hugh Cole
Independent Director
Michael Kishbauch
Independent Director
Gregg Lapointe
  • 分红
  • 拆股
  • 内部人交易
暂无数据
注册即可获得3个月
免费美股Level2深度行情
(Nasdaq Totalview)
立即领取
CATB 简况
Catabasis Pharmaceuticals Inc是一家临床阶段的生物制药公司。该公司专注于治疗剂的发现、开发和商业化。该公司的主要产品候选药物为edasalonexent,这是一种可抑制活化B细胞的核因子κ轻链增强剂的口服小分子药物,目前正在开发中,可用于治疗杜氏肌营养不良症(DMD)。除edasalonexent外,该公司还开发了CAT-5571,作为治疗囊性纤维化(CF)的潜在疗法。CAT-5571是一种可激活自噬的口服小分子。自噬是一种回收细胞成分和消化病原体的机制,对宿主防御有重要作用,会在CF中被抑制。该公司的Safely Metabolized and Rationally Targeted(SMART)是一种链接药物发现平台,可用于设计调节疾病中多个靶点的候选药物。
展开

微牛提供Catabasis Pharmaceuticals Inc(NASDAQ-CATB)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CATB股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CATB股票基本功能。